Cellular Immunology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, 115 27 Athens, Greece.
Molecular Biology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, 115 27 Athens, Greece.
Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2891-E2900. doi: 10.1073/pnas.1616942114. Epub 2017 Mar 20.
Type 1 regulatory T (Tr1) cells play a pivotal role in restraining human T-cell responses toward environmental allergens and protecting against allergic diseases. Still, the precise molecular cues that underlie their transcriptional and functional specification remain elusive. Here, we show that the cytokine activin-A instructs the generation of CD4 T cells that express the Tr1-cell-associated molecules IL-10, inducible T-Cell costimulator (ICOS), lymphocyte activation gene 3 protein (LAG-3), and CD49b, and exert strongly suppressive functions toward allergic responses induced by naive and in vivo-primed human T helper 2 cells. Moreover, mechanistic studies reveal that activin-A signaling induces the activation of the transcription factor interferon regulatory factor (IRF4), which, along with the environmental sensor aryl hydrocarbon receptor, forms a multipartite transcriptional complex that binds in IL-10 and ICOS promoter elements and controls gene expression in human CD4 T cells. In fact, IRF4 silencing abrogates activin-A-driven and up-regulation and impairs the suppressive functions of human activin-A-induced Tr1-like (act-A-iTr1) cells. Importantly, using a humanized mouse model of allergic asthma, we demonstrate that adoptive transfer of human act-A-iTr1 cells, both in preventive and therapeutic protocols, confers significant protection against cardinal asthma manifestations, including pulmonary inflammation. Overall, our findings uncover an activin-A-induced IRF4-aryl hydrocarbon receptor (AhR)-dependent transcriptional network, which generates suppressive human Tr1 cells that may be harnessed for the control of allergic diseases.
1 型调节性 T(Tr1)细胞在抑制人类 T 细胞对环境过敏原的反应并预防过敏疾病方面发挥着关键作用。然而,其转录和功能特化的确切分子线索仍然难以捉摸。在这里,我们表明细胞因子激活素-A 指示产生表达 Tr1 细胞相关分子 IL-10、诱导性 T 细胞共刺激因子(ICOS)、淋巴细胞激活基因 3 蛋白(LAG-3)和 CD49b 的 CD4 T 细胞,并对幼稚和体内致敏的人类辅助性 T 细胞 2 细胞诱导的过敏反应发挥强烈的抑制作用。此外,机制研究表明激活素-A 信号诱导转录因子干扰素调节因子(IRF4)的激活,该因子与环境传感器芳香烃受体一起形成一个多部分转录复合物,结合在 IL-10 和 ICOS 启动子元件上,并控制人类 CD4 T 细胞中的基因表达。事实上,IRF4 的沉默会破坏激活素-A 驱动的 和 上调,并损害人类激活素-A 诱导的 Tr1 样(act-A-iTr1)细胞的抑制功能。重要的是,使用过敏性哮喘的人源化小鼠模型,我们证明了在预防性和治疗性方案中过继转移人类 act-A-iTr1 细胞可显著预防包括肺部炎症在内的主要哮喘表现。总的来说,我们的研究结果揭示了一个激活素-A 诱导的 IRF4-芳香烃受体(AhR)依赖性转录网络,该网络产生了具有抑制作用的人类 Tr1 细胞,可用于控制过敏疾病。